THERAPY DOSSIER · th-f008372cafb0

Dasatinib

Drug · Multi-targeted tyrosine kinase inhibitor (BCR-ABL, SRC family, PDGFR-beta, KIT, EPHA2)

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Multi-targeted tyrosine kinase inhibitor (BCR-ABL, SRC family, PDGFR-beta, KIT, EPHA2)
Target: BCR-ABL (CHEMBL2096618); ABL1 (CHEMBL1862); SRC (CHEMBL2363074); PDGFRB (CHEMBL1913); KIT (CHEMBL1936)
Injury models: Radiation
Reported indication: Not recorded
First approval: 2006
Development stage: Not recorded
ChEMBL record: CHEMBL1421 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Dasatinib; Sprycel; BMS-354825
Note: Not recorded

Clinical trials 4

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05432518 ↗Injury indicationEARLY_PHASE1recruiting

Biomarker-Driven Pilot Trial (incl. Dasatinib) for Recurrent Glioblastoma

Recurrent Glioblastoma

Enrolment: 10 · Results not recorded

NCT01254864 ↗PHASE2completed

Maximal Androgen Ablation With Molecular Targeted Therapies (incl. Dasatinib) in Prostate Cancer

Prostate Cancer

Enrolment: 190 · Results not recorded

NCT04626024 ↗PHASE2active not recruiting

TKI Cessation (incl. Dasatinib) for CML Patients With Stable Molecular Response

Chronic Myeloid Leukemia

Enrolment: 17 · Results not recorded

NCT00560391 ↗PHASE1completed

Dasatinib With Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

Enrolment: 35 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27406443 ↗2016Reported benefit

PrP(c) deficiency and dasatinib protect mouse intestines against radiation injury by inhibiting of c-Src.

MouseRadiationC57BL/6 wild-type and PrP(c)-deficient (knockout)

Model: Total body irradiation causing acute intestinal injury and epithelial barrier dysfunction

PrP(c) deficiency reduced radiation-induced lethality, improved intestinal wound healing and reduced intestinal leakage, and dasatinib treatment reproduced this protection, confirming Src involvement in acute intestinal radiation toxicity.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…